in 2020 have examined Enolase 1 (ENO1)‐targeted SPIONs using the ENO1 antibody to evaluate pancreatic ductal adenocarcinomas (PDACs), which are the deadliest cancer with a 5‐year survival rate of 5% for all stages [1, 54]. Here, ENO1 is linked to pancreatic ductal adenocarcinoma.